Solid-state stability and compatibility studies of clavulanate potassium.
The kinetic and thermodynamic parameters of degradation of clavulanate potassium in the solid state were studied by using a reversed phase high performance liquid chromatography (RP-HPLC) method. The degradation of clavulanate potassium was a first-order reaction depending on the substrate concentration at an increased relative air humidity (RH) and in dry air. The dependence ln k = f(1/T) became the ln k = (0.026 ± 166.35)-(2702.82 ± 1779.43)(1/T) in dry air and ln k = (1.65 ± 100.40) × 10(3)-(5748.81 ± 3659.67)(1/T) at 76.4% RH. The thermodynamic parameters Ea, ΔH(≠a), ΔS(≠a) of the degradation of clavulanate potassium in the solid state were calculated. The dependence ln k = f (RH%) assumed the form ln k = (8.78 ± 5.75) 10 (-2) (RH%) + (2.64 × 10(-8 )± 40.41). The compatibility of clavulanate potassium with commonly used excipients was studied at an increased temperature and in dry air. The geometric structure of molecule, highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) orbitals were also determined in order to predict the structural changes and reactive sites in clavulanate potassium during degradation and compatibility studies in the solid state. The ultraviolet (UV), Fourier transform infrared spectroscopy (FT-IR) and Raman spectra of degraded samples of the compound were analyzed.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences , Poznań , Poland and.
Judyta
J
Cielecka-Piontek
Magdalena
M
Paczkowska
Przemysław
P
Zalewski
Kornelia
K
Lewandowska
Bolesław
B
Barszcz
D056148:Chromatography, Reverse-Phase; D019818:Clavulanic Acid / Q000737:chemistry* / Q000592:standards; D004355:Drug Stability; D005079:Excipients / Q000737:chemistry*; D006813:Humidity; D007700:Kinetics; D008962:Models, Theoretical; D015394:Molecular Structure; D044367:Phase Transition; D013816:Thermodynamics; D065093:beta-Lactamase Inhibitors / Q000737:chemistry* / Q000592:standards
D005079:Excipients; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid
Compatibility studies; pharmaceutical analysis; stability studies